Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose of mebendazole (MBZ) that can be safely
given to people with malignant brain tumors in combination with the current standard of care
(temozolomide) without causing severe side effects. We also want to find out if MBZ can slow
the growth of the brain tumor. The study doctors have found that MBZ is effective against
malignant brain tumors in the laboratory and animal models of brain tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins